Robust scientific research is necessary to provide continued hope for all those diagnosed with lung cancer. LUNGevity's Translational Science Research Program—focused on the second stage of research—aims to take knowledge from basic discovery and apply it to the treatment of disease to give patients access in a clinical setting more quickly.
LUNGevity’s strategic approach to research falls into two priority areas: finding lung cancer early and treating it more effectively. There are LUNGevity award programs to support researchers from postdoctoral fellows through established investigators to harness skill and innovative ideas at all levels.
Research projects are carefully vetted to ensure that we are funding the most impactful science possible. The review process includes a formal study section with Scientific Advisory Board members and other lung cancer experts who identify, among the grant applications we receive, the most promising proposals for research into the early detection and treatment of lung cancer. The lung cancer experts who review the grant applications assess them on a number of measures, including the likelihood that the proposed research will exert a sustained, powerful influence on the research field involved and have a near-term impact on improving lung cancer mortality rates.
LUNGevity strategically adds new award vehicles to leverage and enhance scientific advancements:
LUNGevity thanks our generous research funders Boehringer Ingelheim, Genentech, and Merck.
